Citation

Bryan J. Pharm. J. 2008; 281(7520): 339-340.

Copyright

(Copyright © 2008, Pharmaceutical Press)

DOI

unavailable

PMID

unavailable

Abstract

[Abstract unavailable]

Language: en

Keywords

human; homicide; suicide; ischemic heart disease; primary prevention; United Kingdom; mortality; clinical trial; risk assessment; rhabdomyolysis; article; unclassified drug; fear; drug mechanism; heart infarction; hydroxymethylglutaryl coenzyme A reductase inhibitor; health care cost; follow up; secondary prevention; drug efficacy; cost effectiveness analysis; hypercholesterolemia; simvastatin; high risk patient; non prescription drug; atorvastatin; cerivastatin; fluindostatin; gemfibrozil; mevinolin; pravastatin; patent; risk reduction; drug response; drug potency; neoplasm; clofibrate; colestyramine; cardiovascular risk; clinical effectiveness; compactin; rosuvastatin; zocor heartpro